Form 4: Andrew J. Last Acquires Insight Molecular Diagnostics Stock

Director Andrew J. Last acquired 26,943 shares of Insight Molecular Diagnostics Inc. through a restricted stock unit grant.

Summary

• Director Andrew J. Last received a grant of 26,943 restricted stock units (RSUs) on June 11, 2026.
• The shares were acquired at a price of $0 per share as part of a compensation or incentive arrangement.
• Following this transaction, the total beneficial ownership of Andrew J. Last in the company is 66,452 shares.
• The RSUs are subject to a vesting schedule tied to the next annual meeting of shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation and equity alignment, which is neutral in terms of immediate market impact.

Positives

• Increased alignment between the director and shareholder interests through equity ownership.
• The acquisition reflects ongoing commitment from a member of the board of directors.

Negatives

• None identified in this filing.

Risks

• Vesting of the restricted stock units is contingent upon the director's continued service until the next annual meeting of shareholders.

Future Outlook

The restricted stock units will vest on the date of the next annual meeting of shareholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices intended to align board incentives with long-term shareholder value in the biotechnology and diagnostics sector.

Comparison to Industry Standards

• The use of RSU grants for directors is a common practice among small-cap diagnostic companies to preserve cash while incentivizing board members.
• The vesting schedule tied to the annual meeting is a standard retention mechanism in the industry.

Stakeholder Impact

• Shareholders benefit from increased director equity alignment.

Next Steps

• Vesting of the 26,943 restricted stock units at the next annual meeting of shareholders.

Key Dates

Keywords

Insight Molecular Diagnostics, IMDX, Form 4, Insider Trading, Director Ownership, Restricted Stock Units